[Shandong: Focus on Developing Antibody Drugs for Treating Malignant Tumors, Hematological Diseases, etc.] The "Shandong Province Pharmaceutical Industry '15th Five-Year Plan' Development Action Plan (Draft for Comments)" is open for public comment. It mentions focusing on major infectious diseases, respiratory infections, malignant tumors, drug-resistant infections, autoimmune diseases, metabolic diseases, and central nervous system diseases. The plan calls for accelerating the development of key areas such as monoclonal antibody drugs, bispecific antibodies, trispecific antibodies, antibody-drug conjugates, recombinant proteins, cell and gene therapy drugs, innovative vaccines, and marine biological drugs, promoting breakthroughs in core technologies, and accelerating industrialization. Specifically, it emphasizes the development of antibody drugs for treating malignant tumors, hematological diseases, autoimmune diseases, metabolic diseases, ophthalmic diseases, nervous system drugs, cardiovascular diseases, and anti-infective diseases. Support will be given to the development of innovative technology platforms such as multifunctional antibody drugs, antibody fusion proteins, nanobodies, combination antibodies, antibody combination preparations and high-concentration preparations, as well as novel ADC drugs, to improve industrialization capabilities.
